Literature DB >> 16932910

Suppression of proinflammatory cytokine production in macrophages by lansoprazole.

Akinari Hinoki1, Kazunori Yoshimura, Keiko Fujita, Masumi Akita, Rie Ikeda, Masabumi Nagashima, Masahiko Nomura, Akira Satomi.   

Abstract

Macrophages (MPs) produce increased levels of proinflammatory cytokines in Crohn's disease; these cytokines are thought to play a central role in the occurrence of the disease. Biologics are currently available for anti-cytokine therapy, but treating intestinal inflammation through direct suppression of proinflammatory cytokine production could be more effective. P-ATPase inhibitors have been reported to be anti-inflammatory, and these inhibitors might suppress the production of MP proinflammatory cytokines. In this study, we examined the effect of two types of ATPase inhibitors on the expression patterns of typical proinflammatory cytokines. Peritoneal MPs from 6- to 8-week-old mice were cultured for 48 h in the presence of lansoprazole (P-ATPase inhibitor), bafilomycin A(1) (V-ATPase inhibitor), or the control solvent dimethylsulfoxide. The MPs were then examined for cytokine expression by quantitative real-time polymerase chain reaction (PCR), and culture supernatants were examined for cytokine production with a multiplex assay in a suspension array system. The possible existence of P-ATPase mRNA in MPs was explored using reverse-transcriptase PCR. P-ATPase mRNA was not detected in MP cells. However, all examined proinflammatory cytokines decreased significantly in their mRNA and protein expression in the lansoprazole-treated group. Conversely, bafilomycin A(1) increased the levels of these cytokines. Lansoprazole might be useful for the treatment of inflammatory bowel diseases (IBDs), including Crohn's disease, as it suppresses the production of relevant MP proinflammatory cytokines. However, because P-ATPase was not detected in MPs, the mechanism is unclear and remains to be studied further in an IBD animal model.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16932910     DOI: 10.1007/s00383-006-1767-8

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  29 in total

1.  IL-6 is required for the development of Th1 cell-mediated murine colitis.

Authors:  M Yamamoto; K Yoshizaki; T Kishimoto; H Ito
Journal:  J Immunol       Date:  2000-05-01       Impact factor: 5.422

2.  Omeprazole for duodenal ulceration in Crohn's disease.

Authors:  R M Valori; R Cockel
Journal:  BMJ       Date:  1990-02-17

3.  Effects of omeprazole and gentamicin on the biochemical and histopathological alterations of the hypoxia/ reoxygenation induced intestinal injury in newborn rats.

Authors:  Unal Biçakçi; Burak Tander; Ender Aritürk; Birsen Kiliçoğlu Aydin; Oğuz Aydin; Riza Rizalar; Zafer Eren; Ferit Bernay
Journal:  Pediatr Surg Int       Date:  2005-10-21       Impact factor: 1.827

4.  Bactericidal activity of alveolar macrophages is suppressed by V-ATPase inhibition.

Authors:  A Bidani; B S Reisner; A K Haque; J Wen; R E Helmer; D M Tuazon; T A Heming
Journal:  Lung       Date:  2000       Impact factor: 2.584

5.  A new mechanism for anti-inflammatory actions of proton pump inhibitors--inhibitory effects on neutrophil-endothelial cell interactions.

Authors:  N Yoshida; T Yoshikawa; Y Tanaka; N Fujita; K Kassai; Y Naito; M Kondo
Journal:  Aliment Pharmacol Ther       Date:  2000-04       Impact factor: 8.171

6.  Lansoprazole binding to the neutrophils in dextran sulfate sodium-induced rat colitis.

Authors:  Masahiko Nakamura; Maki Asada; Koichiro Atsuda; Hidenori Matsui; Toshio Watanabe; Kazuhide Higuchi; Tetsuo Arakawa; Norifumi Hibi; Kanji Tsuchimoto
Journal:  Inflammopharmacology       Date:  2005       Impact factor: 4.473

7.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

Authors:  Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2003-02-13       Impact factor: 91.245

Review 8.  Introduction and overview: recent advances in the immunotherapy of inflammatory bowel disease.

Authors:  Toshifumi Hibi; Nagamu Inoue; Haruhiko Ogata; Makoto Naganuma
Journal:  J Gastroenterol       Date:  2003-03       Impact factor: 7.527

9.  H(+)-ATPase, a primary pump for accumulation of neurotransmitters, is a major constituent of brain synaptic vesicles.

Authors:  Y Moriyama; M Futai
Journal:  Biochem Biophys Res Commun       Date:  1990-11-30       Impact factor: 3.575

10.  Comprehensive analysis of intestinal cytokine messenger RNA profile by real-time quantitative polymerase chain reaction in patients with inflammatory bowel disease.

Authors:  Yoshinori Sawa; Nobuhide Oshitani; Kenji Adachi; Kazuhide Higuchi; Takayuki Matsumoto; Tetsuo Arakawa
Journal:  Int J Mol Med       Date:  2003-02       Impact factor: 4.101

View more
  7 in total

1.  Lansoprazole inhibits nitric oxide and prostaglandin E(2) production in murine macrophage RAW 264.7 cells.

Authors:  Shuji Nakagawa; Yuji Arai; Tsunao Kishida; Nobuyuki Hiraoka; Shinji Tsuchida; Hiroaki Inoue; Ryo Sakai; Osam Mazda; Toshikazu Kubo
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

2.  Regulation of apoptosis and innate immune stimuli in inflammation-induced preterm labor.

Authors:  Mukesh K Jaiswal; Varkha Agrawal; Timothy Mallers; Alice Gilman-Sachs; Emmet Hirsch; Kenneth D Beaman
Journal:  J Immunol       Date:  2013-10-25       Impact factor: 5.422

3.  The proton pump inhibitor inhibits cell growth and induces apoptosis in human hepatoblastoma.

Authors:  Toshiya Morimura; Keiko Fujita; Masumi Akita; Masabumi Nagashima; Akira Satomi
Journal:  Pediatr Surg Int       Date:  2008-10       Impact factor: 1.827

4.  Omeprazole antagonizes virulence and inflammation in Salmonella enterica-infected RAW264.7 cells.

Authors:  Speranta Puiac; Aurel Negrea; Agneta Richter-Dahlfors; Laura Plant; Mikael Rhen
Journal:  Antimicrob Agents Chemother       Date:  2009-03-23       Impact factor: 5.191

5.  Effects of Pantoprazole on Systemic and Gastric Pro- and Anti-inflammatory Cytokines in Critically Ill Patients.

Authors:  Hamed Tabeefar; Mohammad Taghi Beigmohammadi; Mohammad Reza Javadi; Mohammad Abdollahi; Ata Mahmoodpoor; Arezoo Ahmadi; Hooshyar Honarmand; Atabak Najafi; Mojtaba Mojtahedzadeh
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

6.  The proton pump inhibitor lansoprazole improves the skeletal phenotype in dystrophin deficient mdx mice.

Authors:  Arpana Sali; Gina M Many; Heather Gordish-Dressman; Jack H van der Meulen; Aditi Phadke; Christopher F Spurney; Avital Cnaan; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

7.  Immune and Inflammatory Responses in GERD and Lansoprazole.

Authors:  Hajime Isomoto; Yoshito Nishi; Yusei Kanazawa; Saburo Shikuwa; Yohei Mizuta; Kenichiro Inoue; Shigeru Kohno
Journal:  J Clin Biochem Nutr       Date:  2007-09       Impact factor: 3.114

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.